Use of ketamine for depression and suicidality in cancer and terminal patients: Review of current data
AIMS Public Health January 1, 2023 Aderonke Oyetunji, C. Blanco Huelga, Kailee Bunte et al. 9 citations
Ketamine may offer rapid relief for depression and suicidality in cancer patients, especially those with advanced disease or near the end of life, where conventional antidepressants often work slowly or poorly. This review of clinical trials and case studies examines ketamine's efficacy and safety as a standalone or combined treatment in this population. The evidence is promising but limited; larger, well-controlled studies with long-term follow-up are needed to confirm effectiveness, safety, and optimal dosing for palliative care.